Keywords
How to Cite
Abstract
The aim of the study was to evaluate the associations between the polymorphism G634C (rs 2010963) of the VEGF-A gene and the level of STEMI biomarkers with double antiplatelet therapy.
Materials and methods. 135 patients were enrolled in the case-control study, including 109 (80.7%) men and 26 (19.3%) women, the average age was 59.21 ± 8.92 years. The control group consisted of 30 healthy individuals. Primary percutaneous coronary intervention (PCI) using bare-metal coronary stent (BMS) was performed in 109 patients, 31 patients underwent systemic thrombolysis. The coronary blood flow was restored at the TIMI ІІІ level. Ultrasound examination of the heart was carried out on 3-5 days of hospitalization and after 6 months of observation. The study of the G634C allelic polymorphism (rs 2010963) of the VEGF-A gene was carried out by the method of polymerase chain reaction (PCR) in real time using the Syntol reagent kit (Russia). The level of VEGF-A was determined on the first day of the disease and after 6 months by enzyme immunoassay using reagents IBLINTERNATIONAL, GMBH, (Germany). Patients were divided into two groups: the first one was “case” group - patients who reached the end point, and the second group was “control” - did not reached. The combined endpoint was defined as: cardiovascular death, recurrent myocardial infarction, the occurrence / progression of heart failure that required hospitalization.
Results. The left ventricular ejection fraction (p = 0.002) and creatinine clearance (p = 0.018) were significantly lower in the case group, the diastolic dysfunction E/E 'was higher in the control group (p = 0.007). The level of VEGF-A is significantly lower in the “case” group, in this group there was a higher frequency of the 634GC + 634CC polymorphism of the VEGF-A gene (p = 0.035). The frequency of treatment with clopidogrel was higher in the case group (p = 0.031), and ticagrelor was more often prescribed in the control group (p = 0.031). Logistic uni-and multivariate analysis showed that independent predictors of adverse events after STEMI were polymorphism 634GC + 634CC of the VEGF-A gene, ejection fraction <50.60% and the clopidogrel antiplatelet therapy in the group of the polymorphic variant of the VEGF-A gene.
Conclusions: The presence of the 634GC + 634CC polymorphism of the VEGF-A gene, ejection fraction <50.60% and the clopidogrel treatment are independent predictors of adverse events in STEMI patients. The administration of ticagrelor against clopidogrel significantly benefit the course of the post-infarction period in patients with STEMI after successful PCI.
References
Kopytsa N. P., Kutya I. N., Hilova Ya. V. (2020). The Role of Mononucleotide G634c VEGF-A Gene Polymorphism in Patients with Myocardial Infarction in Acute and Remote Periods. Ukrainian Journal of Medicine, Biology and Sport, 1(23), 115-124. doi: 10.26693/jmbs05.01.115
Unifikovanyi klinichnyi protokol ekstrenoi, pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) medychnoi dopomohy ta medychnoi reabilitatsii hostryi koronarnyi syndrom z elevatsiieiu sehmenta ST. Nakaz MOZ Ukrainy № 455 vid 02 lypnia 2014. [Unified clinical protocols of emergency, primary, secondary (specialized) and tertiary (highly specialized) care and medical rehabilitation “Acute coronary syndrome with ST-segment elevation” Order, 455]
Berezin A. E. (2014). Predicitive role of circulating vascular endothelial growth factor-1 in patients with cardiovascular diseases. J Dis Markers, 1(3), id1013.
Douvaras P., Antonatos D.G.,Kekou K., Patsilinakos S, Chouliaras G, Christou A, Andrikou A, Kanavakis E. (2009). Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction. Cardiology, 114(1), 11-18.
Fan Z. G., Zhang W. L., Xu B., Ji J., Tian N. L., He, S. H. (2019). Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis. Drug design, development and therapy, 13, 719.
Ferrara N. (2009). Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol, 29(6), 789-91.
Han X., Liu L., Niu J., Yang J., Zhang Z., Zhang Z. (2015). Association between VEGF polymorphisms (936c/t,-460t/c and-634g/c) with haplotypes and coronary heart disease susceptibility. International journal of clinical and experimental pathology, 8(1), 922.
Jeong H.S., Kim J.H., Hong S.J. (2018). Pleiotropic Effects of Ticagrelor Beyond its Potent Antiplatelet Effects Contributing to Additional Clinical Benefits. JACC Cardiovasc Interv, 11(17), 1785. doi: 10.1016/j.jcin.2018.06.016.
Li L., Pan Y., Dai L., Liu B., Zhang D. (2016). Association of genetic polymorphisms on vascular endothelial growth factor and its receptor genes with susceptibility to coronary heart disease. Medical science monitor: international medical journal of experimental and clinical research, 22, 31. doi: 10.12659/MSM.895163
Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W.L., Braunwald E., Sabatine M.S. (2009). Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 119(19), 2553-60. doi: 10.1161/Сirculationaha.109.851949.
Nicholls S.J. (2020). Using genetics to guide treatment and drug development in cardiovascular medicine: time to reveal the proof in the pudding. Cardiovascular Research, 116, Issue 2, e30–e32., doi:10.1093/cvr/cvz284.
Palmerini T., Biondi-Zoccai G., Della Riva D., Stettler C., Sangiorgi D., D'Ascenzo F., Kimura T., Briguori C., Sabatè M., Kim H. S., De Waha A., Kedhi E., Smits P. C., Kaiser C., Sardella G., Marullo A., Kirtane A. J., Leon M. B., Stone G. W. (2012). Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (London, England), 379(9824), 1393–1402. doi: 10.1016 / S0140-6736 (12) 60324-9.
Petrovic D., Verhovec R., Globocnik Petrovic M., Petrovic M., Osredkar J., Peterlin B. (2007). Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology, 107 (4), 291–295.
Ponikowski P., Voors A. A., Anker S. D., Bueno H., Cleland J., Coats A., Falk V., González-Juanatey J. R., Harjola V. P., Jankowska E. A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J. T., Pieske B., Riley J. P., Rosano G., Ruilope L. M., Ruschitzka F., Rutten F. H., … ESC Scientific Document Group (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal, 37(27), 2129–2200. doi: 10.1093/eurheartj/ehw128
Redfors B., Volz S., Angeras O., Haraldsson I., Ioanes D., Odenstedt J., Jacob P., Petur R., Lotta S., Jason W., Magnus A., Per R., Albertsson P., Omerovic E. (2016). TCT-107 Ticagelor is not superior to clopidogrel in patients with acute coronary syndrome–A report from SCAAR. Journal of the American College of Cardiology, 68(18 Supplement), B43.
Sahlén A., Varenhorst C., Lagerqvist B., Renlund H., Omerovic E., Erlinge D., Wallentin L., James S.K., Jernberg T. (2016). Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J, 37(44), 3335-3342. doi: 10.1093/eurheartj/ehw284.
Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A., White H.D.; ESC Scientific Document Group. (2019). Fourth universal definition of myocardial infarction (2018). Eur Heart J, 40(3), 237-269. doi: 10.1093/eurheartj/ehy462.
Turgeon R. D., Koshman S. L., Youngson E., Har B., Wilton S. B., James M. T., Graham M. M. (2020). Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA Internal Medicine. doi:10.1001/jamainternmed.2019.6447.
van der Meer Р., De Boer R.A. , White H.L., Van der Steege G., Hall A.S., Voors A.A., van Veldhuisen D.J. (2005). The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail, 11(4), 279-84.
Wallentin L., Becker R. C., Budaj A., Cannon C. P., Emanuelsson H., Held С.D., Horrow J., Steen Husted, James Sc., S., Katus Н., Mahaffey, M.D K. W., Scirica В. M, et al., for the PLATO Investigators. (2009). Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med, 361, 1045-1057. doi: 10.1056/NEJMoa0904327
Watson C. J., Webb N. J., Bottomley M. J., Brenchley P. E. (2000). Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine, 12(8), 1232-1235. doi: 10.1006/cyto.2000.0692
Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D. L., Coca A., de Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S. E., Kreutz R., Laurent S., Lip G., … ESC Scientific Document Group (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European heart journal, 39(33), 3021–3104. doi: 10.1093/eurheartj/ehy339.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.